Brad Cannon - Smith Nephew President Europe and Canada
SNNUF Stock | USD 12.31 0.40 3.15% |
President
Mr. Brad Cannon is President Sports Medicine ENT of the Company. He Joined Smith Nephew in 2012 and has since been the President of Smith Nephew Europe and Canada business, the Company Chief Marketing Officer, and now serves as the President of the Global Sports Medicine and Ear, Nose and Throat business. He is based in Andover, US. Skills and experience Brad was most recently the Chief Marketing Officer and prior to that the President of Europe and Canada, where he successfully led the commercial business in those regions. He has also served as the President of Global Orthopaedic Franchises, leading Smith Nephews Reconstruction, Endoscopy, Trauma and Extremities businesses. Prior to Smith Nephew, Brad worked in Medtronics Spine and Biologics division. From 2009, he was responsible for Medtronics Spine International division and held positions heading US sales and global commercial operations. Brad is a graduate of Washington and Lee University, and the Wharton School of Business at the University of Pennsylvania. since 2018.
Age | 50 |
Tenure | 6 years |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Meghan Scanlon | Boston Scientific Corp | 48 | |
Michael Reitermann | Siemens Healthineers AG | 55 | |
Bryan Hanson | Medtronic PLC | 49 | |
Hooman Hakami | Medtronic PLC | 48 | |
Jeffrey Moy | DexCom Inc | 57 | |
Joseph Fitzgerald | Boston Scientific Corp | 60 | |
John Sorenson | Boston Scientific Corp | 56 | |
Glenn Boehnlein | Stryker | 62 | |
Scott White | Abbott Laboratories | 46 | |
JeanYves Pavee | Abbott Laboratories | 51 | |
David Pierce | Boston Scientific Corp | 57 | |
Jennifer Erfurth | Align Technology | 45 | |
Eric Fain | Abbott Laboratories | 56 | |
Arthur Butcher | Boston Scientific Corp | 53 | |
Geoffrey Martha | Medtronic PLC | 54 | |
Adam Johnson | Zimmer Biomet Holdings | 37 | |
Joseph Manning | Abbott Laboratories | 55 | |
Michael Rousseau | Abbott Laboratories | 62 | |
Jared Watkin | Abbott Laboratories | 56 | |
Richard Kuntz | Medtronic PLC | 63 | |
Heather Mason | Abbott Laboratories | 56 |
Management Performance
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 |
Smith Nephew Plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director | ||
Michael Friedman, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Director | ||
Deepak Nath, CEO Director | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Director | ||
AnneFrancoise Nesmes, CFO Director | ||
Helen Barraclough, Company Counsel | ||
Rodrigo Bianchi, President IRAMEA | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, Sports Orthopaedics | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Non-Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Director | ||
Simon Fraser, President - Advanced Wound Management | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, CFO, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, VP Communications | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Glenn Warner, President - Advanced Wound Management | ||
Robin Freestone, Non-Executive Director | ||
Paul Connolly, Pres Operations | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Director | ||
Mark Gladwell, President - Global Operations | ||
Andrew Swift, VP Relations | ||
Vasant Padmanabhan, President - Research & Development | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Joseph Papa, Non-Executive Independent Director | ||
Ingeborg Oie, VP, Investor Relations | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President Europe and Canada | ||
Ian Barlow, Non-Executive Independent Director | ||
Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 | |||
Profit Margin | 0.1 % | |||
Operating Margin | 0.14 % | |||
Current Valuation | 14.08 B | |||
Shares Outstanding | 873.35 M | |||
Shares Owned By Insiders | 0.17 % | |||
Shares Owned By Institutions | 52.60 % | |||
Price To Earning | 23.41 X | |||
Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |